-
G610720-5mgGSK-3β inhibitor 3.
-
G338716-1mgGSK-3β Inhibitor XI is a cell-permeable azaindolylmaleimide compound acting as a potent and specific ATP-competitive inhibitor of GSK-3β. GSK-3β Inhibitor XI shows minimal inhibition activity in a panel of 79 commonly studied protein kinases. This
-
-
-
G610738-25mgGSK-Bz derivative 2b.
-
G610738-5mgGSK-Bz derivative 2b.
-
G275049-100mgProduct introductionGSK J1 is a potent and selective inhibitor of the histone H3 lysine 27 (H3K27) demethylase JMJD3, a Fe2+- and α-ketoglutarate-dependent oxygenase involved in a variety of physiological functions including the inflammatory
-
G275049-10mgProduct introductionGSK J1 is a potent and selective inhibitor of the histone H3 lysine 27 (H3K27) demethylase JMJD3, a Fe2+- and α-ketoglutarate-dependent oxygenase involved in a variety of physiological functions including the inflammatory
-
G275049-25mgProduct introductionGSK J1 is a potent and selective inhibitor of the histone H3 lysine 27 (H3K27) demethylase JMJD3, a Fe2+- and α-ketoglutarate-dependent oxygenase involved in a variety of physiological functions including the inflammatory
-
G275049-50mgProduct introductionGSK J1 is a potent and selective inhibitor of the histone H3 lysine 27 (H3K27) demethylase JMJD3, a Fe2+- and α-ketoglutarate-dependent oxygenase involved in a variety of physiological functions including the inflammatory
-
G276086-100mgProduct Application: GSK-J4 has been used to study the effect of KDM2B (Jumonji (JmjC) domain histone 3 lysine 36 (H3K36) di-demethylase) inhibition on the survival and DNA repair potential of glioblastoma cells. It has also been used in
-
G276086-10mgProduct Application: GSK-J4 has been used to study the effect of KDM2B (Jumonji (JmjC) domain histone 3 lysine 36 (H3K36) di-demethylase) inhibition on the survival and DNA repair potential of glioblastoma cells. It has also been used in